Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Postoperative Radiotherapy With Tyrosine Kinase Inhibitor (Anlotinib) for Resectable Soft Tissue Sarcoma With High Recurrence Risk

NCT05602415 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05602415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Postoperative Radiotherapy With Tyrosine Kinase Inhibitor (Anlotinib) for Resectable Soft Tissue Sarcoma With High Recurrence Risk
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2022
Completion date
May 31, 2024
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, high risk of recurrence, radiotherapy, soft tissue sarcoma